title: Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial.
abstract: OBJECTIVE
  We investigated clinical outcomes after treatment of coronary bifurcation lesions with second generation drug eluting stents (DES).
  
  
  METHODS
  Post hoc analysis of a randomised, multicentre, non-inferiority trial.
  
  
  METHODS
  Multicentre study.
  
  
  METHODS
  All comers study with minimal exclusion criteria.
  
  
  METHODS
  Patients were treated with either zotarolimus or everolimus eluting stents. The patient population was divided according to treatment of bifurcation or non-bifurcation lesions and clinical outcomes were compared between groups.
  
  
  METHODS
  Clinical outcomes within 2-year follow-up.
  
  
  RESULTS
  A total of 2265 patients were included in the present analysis. Two-year follow-up data were available in 2223 patients: 1838 patients in the non-bifurcation group and 385 patients in the bifurcation group. At 2-year follow-up the bifurcation and the non-bifurcation lesion groups showed no significant differences in terms of cardiac death (2.3 vs 2.1, p=0.273), target lesion failure (9.7% vs 13.8%, p=0.255), major adverse cardiac events (11.5% vs 15.1%, p=0.305), target lesion revascularisation (4.7% vs 6.0%, p=0.569), and definite or probable stent thrombosis (1.6% vs 1.8%, p=0.419).
  
  
  CONCLUSIONS
  The use of second generation DES for the treatment of coronary bifurcation lesions was associated with similar long term mortality and clinical outcomes compared with non-bifurcation lesions.
authors.affiliation: Department of Interventional Cardiology Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands.
authors.forename: Roberto
authors.initials: R
authors.lastname: Diletti
authors.forename: Hector M
authors.initials: HM
authors.lastname: Garcia-Garcia
authors.forename: Christos V
authors.initials: CV
authors.lastname: Bourantas
authors.forename: Robert Jan
authors.initials: RJ
authors.lastname: van Geuns
authors.forename: Nicolas M
authors.initials: NM
authors.lastname: Van Mieghem
authors.forename: Pascal
authors.initials: P
authors.lastname: Vranckx
authors.forename: Yao-Jun
authors.initials: YJ
authors.lastname: Zhang
authors.forename: Vasim
authors.initials: V
authors.lastname: Farooq
authors.forename: Javaid
authors.initials: J
authors.lastname: Iqbal
authors.forename: Joanna J
authors.initials: JJ
authors.lastname: Wykrzykowska
authors.forename: Ton
authors.initials: T
authors.lastname: de Vries
authors.forename: Michael
authors.initials: M
authors.lastname: Swart
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Teunissen
authors.forename: Manuela
authors.initials: M
authors.lastname: Negoita
authors.forename: Frank
authors.initials: F
authors.lastname: van Leeuwen
authors.forename: Sigmund
authors.initials: S
authors.lastname: Silber
authors.forename: Stephan
authors.initials: S
authors.lastname: Windecker
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods* / Q000401:mortality; D016016:Proportional Hazards Models; D011446:Prospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus